BiotechTube
PharmaLundensis

PharmaLundensis

Lund, Sweden· Est.
pharmalundensis.se
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

PharmaLundensis is a preclinical-stage biotech developing Phal-501, a novel oral chelator for heavy metal detoxification. The company is seeking $6 million in funding to advance into GMP production and proof-of-concept clinical studies in COPD and chronic fatigue syndrome. Founded and led by physician-scientist Staffan Skogvall, the company is publicly traded in Sweden but remains pre-revenue, with its technology protected by a recently published patent application. Key risks include early-stage development, clinical validation, and securing necessary financing.

COPDChronic Fatigue SyndromeHeavy Metal Toxicity

Technology Platform

Design of non-absorbed, oral small molecule chelators that bind heavy metals (e.g., mercury, lead, cadmium) in the gastrointestinal tract for direct excretion in stool.

Opportunities

If successful, Phal-501 could address large, underserved chronic disease markets like COPD and chronic fatigue syndrome with a first-in-class mechanism.
The non-systemic, oral approach offers a potential safety and convenience advantage over traditional chelation therapies, potentially enabling chronic use for preventative or maintenance treatment in exposed populations.

Risk Factors

The core scientific hypothesis linking heavy metal chelation to efficacy in complex chronic diseases is unproven and faces clinical validation risk.
The company is pre-revenue and reliant on securing a $6M financing round to advance its lead program; failure would halt operations.
Regulatory pathways for this novel drug class are uncertain.

Competitive Landscape

Direct competition in the pharmaceutical heavy metal chelation space for chronic diseases is limited, but the approach competes with all other therapies in development for COPD and CFS. Established chelators (e.g., DMSA, DMPS) are used off-label but are systemic and not optimized for chronic conditions. Large pharma companies are active in COPD with different mechanisms.

More companies in Sweden →